This is the English translation of a Japanese press release published on June 18, 2025. If there are any differences in content or interpretation, the Japanese version shall prevail.

June 18, 2025

Notification Regarding Approval for Partial Change in Approval Matters for Primary Palmar Hyperhidrosis Treatment Drug APOHIDE_® Lotion 20% with New Capacity of 18 mL (17.28 g) in Japan

Hisamitsu Pharmaceutical Co., Inc. (President and CEO: NAKATOMI, Kazuhide) is pleased to announce that it has obtained approval for a partial change in approval matters regarding the addition of a new capacity of 18 mL (17.28 g) of APOHIDE® Lotion 20% for the primary palmar hyperhidrosis treatment drug (generic name: oxybutynin hydrochloride) in Japan as of today.

Primary palmar hyperhidrosis is a disorder characterized by excessive bilateral sweating from the palms and is known to be a major factor that significantly reduces the quality of life and work efficiency in various aspects of school and social life, as it significantly interferes with social activities (e.g., handshaking), paperwork, and operation of electronic devices.¹⁾

In June 2023, we launched APOHIDE® Lotion 20%, which is the first insurance-covered treatment for primary palmar hyperhidrosis in Japan. We are pleased that many patients have used our product since its launch. However, the previous 4.5 mL (4.32 g) version only contained enough lotion for approximately 7 days, which was inconvenient for patients as they had to visit clinics frequently and dispose of the container multiple times. To address these issues and fulfill patient requests, the company developed a larger 18 mL (17.28 g) version that contains enough lotion for approximately 28 days. We are pleased to announce that we have now obtained approval for this change.

Hisamitsu Pharmaceutical improves the quality of life for patients with primary palmar hyperhidrosis by providing accurate and comprehensive information about the product.

[Product information]

| Brand name | APOHIDE _® Lotion 20% |
|-------------------------------|--|
| Generic name | Oxybutynin hydrochloride |
| Indications | Primary palmar hyperhidrosis |
| Dosage and administration | Apply an appropriate amount to the entire palm of both |
| | hands once a day before bedtime. |
| Precautions concerning dosage | Use approximately five pumps of the product for both |
| and administration | palms in one application. |
| Drug price | 543.70 yen/g |
| Contents per bottle | 18 mL (17.28 g) |
| Drug price per bottle | 9,395.136 yen |
| Packaging | 18 mL (17.28 g) × 4 bottles |
| Manufacturing and marketing | June 18, 2025 |
| approval date | |
| On sale from | July 15, 2025 |

[Reference]

APOHIDE® Lotion 20% packaging list


4.5 mL (4.32 g) × 10 bottles

 $4.5 \text{ mL} (4.32 \text{ g}) \times 20 \text{ bottles}$

18 mL (17.28 g) × 4 bottles

[Environmental Considerations for APOHIDE® Lotion 20% 18 mL (17.28 g)]

•The inner layer of the container uses 96% biomass polyethylene (PE) (96% of the raw material is plant-derived PE, such as sugarcane).





HELLO! eco! Mark²⁾

[Source]

- 1) The Japanese Dermatological Association Guidelines: Guidelines for the Treatment of Primary Focal Hyperhidrosis, revised 2023.
- 2) Hisamitsu Pharmaceutical displays HELLO! eco! mark on products that satisfy any of the following ecology standards:
 - (1) Product with sachets or cases reduced in size, compared with our conventional or representative products.
 - (2) Products made from raw materials (plant-derived materials, reused materials, etc.) that can reduce environmental burden.
 - (3) Products that have reduced environmental impact throughout the product lifecycle, compared with our conventional or representative products.

 HELLO! eco! website: https://global.hisamitsu/sustainability/hello-eco.html